[{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Conestat alfa","moa":"C1 esterase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Conestat alfa","moa":"C1 esterase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Autologous Hematopoietic Stem Cell Gene Therapy","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Pharming","amount2":0.20999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Pharming \/ Pharming","highestDevelopmentStatusID":"4","companyTruncated":"Pharming \/ Pharming"},{"orgOrder":0,"company":"Pharming","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Conestat Alfa","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Solution for Injection","sponsorNew":"Pharming \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K delta","graph1":"Immunology","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Pharming \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Abliva","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"KL1333","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Pharming \/ Pharming","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Pharming"},{"orgOrder":0,"company":"Pharming","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Leniolisib Phosphate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Pharming \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharming \/ Not Applicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3K-delta","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pharming \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Pharming
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
